Apollo Hospitals Reports Strong FY26 Performance and Strategic Divestment

Apollo Hospitals Enterprise Limited announced impressive financial results for FY26, with consolidated revenue reaching ₹25,229 crore, marking a 16% year-on-year increase. Consolidated Profit After Tax (PAT) saw a significant jump of 34% to ₹1,942 crore. For the fourth quarter of FY26, consolidated revenue grew 18% to ₹6,605 crore, while PAT rose 36% to ₹529 crore.

Financial Highlights for FY26 and Q4 FY26

Apollo Hospitals Enterprise Limited disclosed its financial performance for the fiscal year ending March 31, 2026 (FY26) and the fourth quarter (Q4 FY26). The company reported consolidated revenue of ₹25,229 crore for FY26, an increase of 16% over the previous year. Consolidated Profit After Tax (PAT) for the full year stood at ₹1,942 crore, a substantial 34% rise year-on-year. EBITDA for FY26 also grew by 25% to ₹3,769 crore.

In Q4 FY26, the company's consolidated revenue was ₹6,605 crore, up 18% year-over-year, and PAT increased by 36% to ₹529 crore. EBITDA for the quarter rose 31% to ₹1,011 crore.

Strategic Divestment and Mergers Approved

Key strategic decisions were also approved by the board. These include the divestment of stakes in Apollo Specialty Hospitals (ASHPL) and Apollo Fertility Centre (AFCPL) by Apollo Health and Lifestyle Limited (AHLL) to Kids Clinic India Limited for ₹1,550 crore. Additionally, the merger of its wholly-owned subsidiary, Apollo Hospitals North Limited, into the parent company was approved for operational consolidation.

The Board recommended a final dividend of ₹10 per equity share for FY26. Re-appointments of Dr. Prathap C Reddy as Executive Chairman and Ms. Rama Bijapurkar as Independent Director were also approved, ensuring leadership continuity.

Significance of the Results and Decisions

These strong financial results indicate robust operational performance and growth in the healthcare sector. The strategic divestment and merger are aimed at streamlining operations and focusing on core areas, potentially enhancing shareholder value. The dividend payout reflects the company's profitability and commitment to returning value to its shareholders.

Company Background

Apollo Hospitals has been a leading integrated healthcare provider in India for decades. The company has consistently expanded its network of hospitals, diagnostic centres, and pharmacies. Recent years have seen a focus on strengthening its specialty services and digital health initiatives.

Impact of the Changes

Following the AHLL transaction, ASHPL and AFCPL will no longer be subsidiaries of Apollo Hospitals Enterprise Limited. AHLL will retain a 9.9% equity stake in the combined entity with Kids Clinic India (Cloudnine). The merger of Apollo Hospitals North Limited aims to create a more unified operational structure. The company will also proceed with dividend distribution and the re-appointments of key board members are confirmed.

Potential Risks

The AHLL transaction is subject to regulatory approvals, notably from the Competition Commission of India (CCI), and other customary closing conditions. The merger of Apollo Hospitals North Ltd requires statutory approvals via the National Company Law Tribunal (NCLT). Delays or adverse rulings on these fronts could impact the expected outcomes.

Competitive Landscape

Apollo Hospitals operates in a competitive healthcare landscape with other major players like Fortis Healthcare, Max Healthcare, and Narayana Hrudayalaya. Its consistent revenue and profit growth demonstrate its strong market position. The company's scale and integrated service offerings are key differentiators.

Key Performance Metrics

• Consolidated Revenue FY26: ₹25,229 crore (16% YoY growth)
• Consolidated PAT FY26: ₹1,942 crore (34% YoY growth)
• Consolidated EBITDA FY26: ₹3,769 crore (25% YoY growth)
• Consolidated Revenue Q4 FY26: ₹6,605 crore (18% YoY growth)
• Consolidated PAT Q4 FY26: ₹529 crore (36% YoY growth)
• Consolidated EBITDA Q4 FY26: ₹1,011 crore (31% YoY growth)

What to Monitor Next

Investors will be watching for the timely receipt of regulatory approvals for the AHLL divestment and the merger of Apollo Hospitals North Ltd. Shareholder approval at the AGM for the dividend and re-appointments, along with the successful completion of the AHLL transaction by the indicative date of October 31, 2026, will be key indicators.